Indeed, our data indicate limiting syndecan‐2 (by SDC2 knockdown or syndecan‐2 peptide overexpression) in TASCs attenuates TGFβ signalling within the breast TME reducing tumour growth and metastasis. This evidence concerns the gene SDC2 and neoplasm.